Last updated: 2026-09-16 10:31:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Nephros Inc. (NEPH) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $4,30, with a market capitalisation of $48,11M and a P/E ratio of 26,84. Over the past 52 weeks, its price has ranged from $2,66 to $6,42. This page covers its latest market performance, valuation, price trends and company information.
$48,11M | |
$4,54 | |
$11,67 | |
$0,91 | |
$4,43 | |
11,69K | |
20,95K | |
26,84 | |
$6,42 | |
$2,66 | |
-- | |
-- |
Nephros Inc. (NEPH) is trading at $4,43 in pre-market trading as of 2026-09-15 23:31:00, down 0,05% ($0,00) from the previous close of $4,43
Pre-market trading shows how investors are pricing NEPH before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Over the past seven days, Nephros Inc. (NEPH) moved from $4,06 to $4,30, representing a gain of 5,81% ($0,24).
The stock traded between $4,06 and $4,75 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.
The average daily volume was 26,08 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 43,5%
NEPH is currently trading at $4,30, placing it 43,5% of the way from its 52-week low of $2,66 to its 52-week high of $6,42. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 36 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Nephros Inc. (NEPH) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.